Author:
Hoepner Robert,Rodgers Stephanie,Stegmayer Katharina,Steinemann Nina,Haag Christina,Calabrese Pasquale,Manjaly Zina-Mary,Salmen Anke,Kesselring Jürg,Zecca Chiara,Gobbi Claudio,Puhan Milo A.,Walther Sebastian,von Wyl Viktor
Abstract
AbstractThe aim of our study was to investigate whether self-reported feeling of loneliness (FoL) and COVID-19-specific health anxiety were associated with the presence of depressive symptoms during the first coronavirus disease 2019 (COVID-19) wave. Questionnaires of 603 persons of the Swiss Multiple Sclerosis Registry (SMSR) were cross-sectionally analyzed using descriptive and multivariable regression methods. The survey response rate was 63.9%. Depressive symptoms were assessed by the Beck Depression Inventory-Fast Screen (BDI-FS). COVID-19-specific health anxiety and FoL were measured using two 5-item Likert scaled pertinent questions. High scoring FoL (2.52, 95% confidence interval (CI) (2.06—2.98)) and/or COVID-19 specific health anxiety (1.36, 95% CI (0.87–1.85)) were significantly associated with depressive symptoms. Further stratification analysis showed that the impact of FoL on depressive symptoms affected all age groups. However, it was more pronounced in younger PwMS, whereas an impact of COVID-19 specific health anxiety on depressive symptoms was particularly observed in middle-aged PwMS. FoL and COVID-19-specific health anxiety were age-dependently associated with depressive symptoms during the first COVID-19 wave in Switzerland. Our findings could guide physicians, health authorities, and self-help groups to better accompany PwMS in times of public health crises.
Funder
Schweizerische Multiple Sklerose Gesellschaft
Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Almirall, Chiesi
Hartmann-Müller Foundation
Bristol Myers Squibb, Novartis, Roche, Baasch Medicus Foundation
Abbvie, Almirall, Biogen Idec, Bristol Meyer Squibb, Genzyme, Lundbeck, Merck, Novartis, Teva Pharma, Roche
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Brauner, J. M. et al. Inferring the effectiveness of government interventions against COVID-19. Science 371(6531), eabd9338 (2021).
2. Scheidegger, D., Fumeaux, T., Hurst, S. & Salathe, M. COVID-19 pandemic: Triage for intensive-care treatment under resource scarcity. Swiss Med. Wkly 150, 20229 (2020).
3. Balto, J. M., Pilutti, L. A. & Motl, R. W. Loneliness in multiple sclerosis: Possible antecedents and correlates. Rehabil. Nurs. 44(1), 52–59 (2019).
4. Garjani, A. et al. Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS register. Mult. Scler. J. https://doi.org/10.1177/13524585211020435 (2021).
5. Kehler, M. D. & Hadjistavropoulos, H. D. Is health anxiety a significant problem for individuals with multiple sclerosis?. J. Behav. Med. 32(2), 150–161 (2009).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献